יחס חוב לטווח קצר להון עצמי: Protagenic Therapeutics, Inc. (PTIX)

The price action visualization for Protagenic Therapeutics (PTIX) on the GURU.Markets platform shows the metric at 0.00, while the business leverages executive expertise in the CNS field and strict control over R&D costs. Protagenic Therapeutics (PTIX) is currently launching primary clinical trials for new psychiatric disorder treatments to attract investment, which will culminate in the release of safe peptide-based antidepressants.

Developing synthetic peptides to combat depression within strict ESG standards, Protagenic Therapeutics (PTIX) maintains financial stability through liability control, where the current value of 0.00 reflects the ratio of short-term loans to net equity, allowing investors to assess liquidity risk and the company's solvency by tracking the dynamics of debt under one year relative to equity.